# Biologic Treatments

Biologic drugs selectively block targets such as IL-17 and IL-23 in psoriasis and IL-4/13 in eczema. They are considered in moderate-to-severe, resistant disease after screening.

## How it is applied

1. Before starting, infection, tuberculosis and laboratory screening confirm suitability.
2. Depending on the target, IL-17, IL-23 or IL-4/13 (dupilumab-class) agents are chosen.
3. Given by injection at set intervals, with response measured by PASI/EASI/DLQI.
4. Follow-up visits review side effects and infection signs before treatment continues.

## Who it suits

- Moderate-to-severe plaque psoriasis or atopic eczema unresponsive to topicals and light.
- People with joint involvement or widespread disease that clearly harms quality of life.
- Selected patients unsuitable for, or inadequately controlled on, systemic therapy.

## Important note

Biologics can raise infection risk, so pre-treatment screening and vaccination status are reviewed and monitoring is essential.

---
Source: https://clinoviaturkey.com/en/treatments/biologic-treatments/ · Clinovia · last reviewed 2026-10-02 · Full clinic profile: https://clinoviaturkey.com/llms-full.txt
